Biolex Therapeutics is a technology company.
Biolex Therapeutics has raised $126.0M across 3 funding rounds.
Biolex Therapeutics has raised $126.0M in total across 3 funding rounds.
Biolex Therapeutics has raised $126.0M in total across 3 funding rounds.
Biolex Therapeutics's investors include OrbiMed, Atlas Venture.
Biolex Therapeutics was a clinical-stage biopharmaceutical company headquartered in Pittsboro, North Carolina, in the Research Triangle area, specializing in the development of hard-to-make therapeutic proteins and optimized monoclonal antibodies using its patented LEX System.[1][2][4] The LEX System genetically engineered the aquatic plant *Lemna* (duckweed) as a host for producing complex biologics like multimeric proteins, interferon alfa-2b, and monoclonal antibodies, enabling efficient, scalable manufacturing that traditional methods struggled with.[1][2][4] It served pharmaceutical partners and pursued its own pipeline, including Locteron for hepatitis C treatment, through collaborations with firms like OctoPlus, Centocor, and Medarex, but ceased operations after filing for Chapter 7 bankruptcy in 2012, selling its LEX technology to Synthon.[2][4]
Founded in 1997 as a privately held biotech firm, Biolex raised $190 million from investors including Quaker BioVentures, The Trelys Funds, and Polaris Venture Partners.[4] Key expansions included acquiring Epicyte Pharmaceutical in 2004 for plantibody technology and LemnaGene SA (France) in 2005, which provided the core *Lemna*-based LEX platform.[2][4] Early traction came from partnerships like four collaborations in 2004 with Bayer HealthCare, Centocor, and Debiopharm for ten proteins, alongside facility growth from 45 to 90 employees by 2007 to support clinical-scale production.[2][4] Pivotal moments included a 2007 strategic alliance with Centocor and Phase II trials for Locteron, but financial pressures led to bankruptcy in 2012.[1][4]
Biolex rode the early 2000s wave of plant-based biomanufacturing, a trend seeking alternatives to costly mammalian cell systems for biologics amid rising demand for monoclonal antibodies and hard-to-express proteins.[2][4] Timing aligned with biotech's shift toward scalable, sustainable platforms post-genomics boom, leveraging *Lemna*'s natural advantages in sterile, contained growth to cut costs and speed development—vital as hepatitis C and oncology markets exploded.[1][2] Market forces like high manufacturing expenses for complex proteins favored its model, influencing the ecosystem by pioneering "plantibodies" and inspiring subsequent plant-cell tech (e.g., acquired assets advanced by Synthon).[4] Though bankrupt, Biolex validated duckweed expression, contributing to broader adoption of non-animal hosts in biopharma.[2][4]
Biolex's innovative LEX System represented a bold bet on plant-based biotech that achieved clinical proof-of-concept but succumbed to funding droughts common in the era's volatile biopharma landscape. Post-2012 sale, its technology lived on through Synthon, potentially fueling next-gen antibodies like BLX-301 in oncology.[4] Looking ahead, trends in biofoundry automation, glyco-engineering, and sustainable biomanufacturing—accelerated by post-2020 supply chain pressures—could revive *Lemna*-style platforms, evolving Biolex's legacy into tools for affordable, green biologics production and reshaping access to complex therapies.
Biolex Therapeutics has raised $126.0M across 3 funding rounds. Most recently, it raised $60.0M Series D in October 2008.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2008 | $60.0M Series D | OrbiMed | |
| May 1, 2007 | $30.0M Series C | Atlas Venture | |
| Aug 1, 2005 | $36.0M Series B | Atlas Venture |